21:38 , Aug 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Melding bispecifics and CAR T cells to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An anti-EGFRvIII CAR T cell engineered to secrete an anti-CD3, anti-EGFR bispecific antibody could treat glioblastoma. In a mouse model of EGFRvIII-positive or EGFRvIII-negative glioblastoma, the engineered cells decreased...
20:13 , Aug 15, 2019 |  BC Innovations  |  Translation in Brief

Marrying CARs and bispecifics for solid tumors

Companies are split on whether CAR T cells or bispecifics will be most efficacious in solid tumors, but one group thinks the best bet is to combine the approaches. A Harvard Medical School team unveiled...
23:48 , Aug 13, 2019 |  BC Extra  |  Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

Pharming licenses Novartis autoimmune candidate  Pharming Group N.V. (Euronext:PHARM) gained rights to PI3Kδ inhibitor CDZ173 from Novartis AG (NYSE:NVS; SIX:NOVN) for patients with activated PI3Kδ syndrome, a primary immune deficiency. Novartis will receive $20 million...
02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
21:35 , Aug 9, 2019 |  BC Extra  |  Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

Biomarker data lift Lexicon   Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week follow-up data from two Phase III trials showing that Zynquista sotagliflozin lowered biomarker levels of chronic...
18:56 , Aug 9, 2019 |  BC Extra  |  Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC. AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved...
23:30 , Aug 2, 2019 |  BC Extra  |  Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Rakuten Medical raises another $100 million  Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series C-1 round from existing investor Rakuten Inc. (Tokyo:4755), giving the Japanese internet giant a 22.6% stake. The...
23:05 , Jul 31, 2019 |  BC Extra  |  Clinical News

July 31 Clinical Quick Takes: Novartis' Kisqali shows OS benefit; plus Atlantic and Translate Bio

Kisqali improves survival for postmenopausal breast cancer  Novartis AG (NYSE:NVS; SIX:NOVN) reported interim data showing CDK4/CDK6 inhibitor Kisqali ribociclib plus fulvestrant met the secondary endpoint of significantly improved overall survival in the Phase III MONALEESA-3...
21:23 , Jul 25, 2019 |  BC Innovations  |  Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; lymphoma; solid tumors Innate Pharma S.A. showed that its trifunctional NK cell engager platform could be deployed against lymphoma, lung cancer and solid tumors. The trifunctional NK cell engagers...
23:19 , Jul 15, 2019 |  BC Extra  |  Financial News

July 15 Financial Quick Takes: RA raises $300M for new fund; plus Alphamab and Castle

RA launches $300M VC fund  RA Capital raised $300 million for its first close-ended venture fund, dubbed Nexus, which will invest in private companies backed by the firm's main fund, RA Capital Healthcare Fund L.P....